Literature DB >> 7191270

Influence of triamterene and hydroxytriamterene sulfuric acid ester on diuresis and saluresis in rats after oral and intravenous application.

G Leilich, H Knauf, E Mutschler, K D Völger.   

Abstract

Previous transport measurements on the submaxillary duct of the rat, the model epithelium for the distal nephron, showed that even the phase-II metabolite of triamterene (TA), hydroxytriamterene sulfuric acid ester (OH-TA-ester), has a diuretic effect. The present studies were aimed at answering the question whether or not this finding was also valid in vivo. Clearance measurements in the rat after i.v. injection of OH-TA-ester did result in an increased diuresis and natriuresis. In comparison with the native triamterene the phase -II metabolite caused only a relative potassium retention. The ester was inactive when administered orally. The potassium loss after administration of furosemide could be prevented by simultaneous i.v. administration of the OH-TA-ester.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7191270

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  4 in total

1.  Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis.

Authors:  A E Busch; H Suessbrich; K Kunzelmann; A Hipper; R Greger; S Waldegger; E Mutschler; B Lindemann; F Lang
Journal:  Pflugers Arch       Date:  1996-09       Impact factor: 3.657

2.  Pharmacokinetics of triamterene and its metabolite in man.

Authors:  J Hasegawa; E T Lin; R L Williams; F Sörgel; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

3.  [Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders].

Authors:  E Mutschler; H J Gilfrich; H Knauf; W Möhrke; K D Völger
Journal:  Klin Wochenschr       Date:  1983-09-15

4.  Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.

Authors:  H J Gilfrich; G Kremer; W Möhrke; E Mutschler; K D Völger
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.